Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-03-12

AUTHORS

Saadettin Kilickap, Sevgen Onder, Omer Dizdar, Mustafa Erman, Aysegul Uner

ABSTRACT

Because of the rapid response to crizotinib, patients with ALK-positive locally advanced disease may become resectable with the use of neoadjuvant crizotinib. A 41-year-old never-smoking man who presented with asthma attack was found to have a suspicious lesion on chest X-ray after. Pathological examination was consistent with ALK(+), the signet-ring cell adenocarcinoma. Surgery was not performed because of mediastinal invasion of the mass. After 4 weeks of crizotinib treatment, a major response was achieved and the tumor became completely cavitary. Short-term neoadjuvant therapy with crizotinib for 4 weeks might be a promising therapy in locally advanced ALK-positive NSCLC and might provide a chance for resectability. More... »

PAGES

1-2

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-019-03810-9

DOI

http://dx.doi.org/10.1007/s00280-019-03810-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112703048

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30863883


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Hacettepe University", 
          "id": "https://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Department of Medical Oncology, Hacettepe University Institute of Cancer, Hamamonu, 06100, Ankara, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kilickap", 
        "givenName": "Saadettin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hacettepe University", 
          "id": "https://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Onder", 
        "givenName": "Sevgen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hacettepe University", 
          "id": "https://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Department of Medical Oncology, Hacettepe University Institute of Cancer, Hamamonu, 06100, Ankara, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dizdar", 
        "givenName": "Omer", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hacettepe University", 
          "id": "https://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Department of Medical Oncology, Hacettepe University Institute of Cancer, Hamamonu, 06100, Ankara, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Erman", 
        "givenName": "Mustafa", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hacettepe University", 
          "id": "https://www.grid.ac/institutes/grid.14442.37", 
          "name": [
            "Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uner", 
        "givenName": "Aysegul", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/jto.0b013e3181c4dedb", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003976586"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1408440", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005474865"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(15)60294-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015414635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.33.7089", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024728994"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1214886", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046181766"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-03-12", 
    "datePublishedReg": "2019-03-12", 
    "description": "Because of the rapid response to crizotinib, patients with ALK-positive locally advanced disease may become resectable with the use of neoadjuvant crizotinib. A 41-year-old never-smoking man who presented with asthma attack was found to have a suspicious lesion on chest X-ray after. Pathological examination was consistent with ALK(+), the signet-ring cell adenocarcinoma. Surgery was not performed because of mediastinal invasion of the mass. After 4 weeks of crizotinib treatment, a major response was achieved and the tumor became completely cavitary. Short-term neoadjuvant therapy with crizotinib for 4 weeks might be a promising therapy in locally advanced ALK-positive NSCLC and might provide a chance for resectability.", 
    "genre": "non_research_article", 
    "id": "sg:pub.10.1007/s00280-019-03810-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }
    ], 
    "name": "Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability", 
    "pagination": "1-2", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "00ba3341e3054532101e612316f3547adadebb582f3ce26749a779c1f825e754"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30863883"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-019-03810-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112703048"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-019-03810-9", 
      "https://app.dimensions.ai/details/publication/pub.1112703048"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000358_0000000358/records_127463_00000011.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00280-019-03810-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03810-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03810-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03810-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-019-03810-9'


 

This table displays all metadata directly associated to this object as RDF triples.

102 TRIPLES      21 PREDICATES      31 URIs      18 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-019-03810-9 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 schema:author N34fdfbe78a944a7290fce51e4ddefd7b
4 schema:citation https://doi.org/10.1016/s0140-6736(15)60294-x
5 https://doi.org/10.1056/nejmoa1214886
6 https://doi.org/10.1056/nejmoa1408440
7 https://doi.org/10.1097/jto.0b013e3181c4dedb
8 https://doi.org/10.1200/jco.2010.33.7089
9 schema:datePublished 2019-03-12
10 schema:datePublishedReg 2019-03-12
11 schema:description Because of the rapid response to crizotinib, patients with ALK-positive locally advanced disease may become resectable with the use of neoadjuvant crizotinib. A 41-year-old never-smoking man who presented with asthma attack was found to have a suspicious lesion on chest X-ray after. Pathological examination was consistent with ALK(+), the signet-ring cell adenocarcinoma. Surgery was not performed because of mediastinal invasion of the mass. After 4 weeks of crizotinib treatment, a major response was achieved and the tumor became completely cavitary. Short-term neoadjuvant therapy with crizotinib for 4 weeks might be a promising therapy in locally advanced ALK-positive NSCLC and might provide a chance for resectability.
12 schema:genre non_research_article
13 schema:inLanguage en
14 schema:isAccessibleForFree false
15 schema:isPartOf sg:journal.1088364
16 schema:name Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability
17 schema:pagination 1-2
18 schema:productId N0c9b675fe40541e7b48e3b176cda165b
19 Nc1115419ff914217ac3f9cec5f7e4c1e
20 Nd2140ae477f548a6942ed6207ae377cc
21 Ne5a5c55642564b1b82b3cf5f21d03c9c
22 Ne68487cd6b9e4887bdb1f8a4f51c8f1f
23 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112703048
24 https://doi.org/10.1007/s00280-019-03810-9
25 schema:sdDatePublished 2019-04-11T11:48
26 schema:sdLicense https://scigraph.springernature.com/explorer/license/
27 schema:sdPublisher N18d9197e1e454f5f96b4ea223f22b5f8
28 schema:url https://link.springer.com/10.1007%2Fs00280-019-03810-9
29 sgo:license sg:explorer/license/
30 sgo:sdDataset articles
31 rdf:type schema:ScholarlyArticle
32 N0c9b675fe40541e7b48e3b176cda165b schema:name dimensions_id
33 schema:value pub.1112703048
34 rdf:type schema:PropertyValue
35 N18d9197e1e454f5f96b4ea223f22b5f8 schema:name Springer Nature - SN SciGraph project
36 rdf:type schema:Organization
37 N34fdfbe78a944a7290fce51e4ddefd7b rdf:first N3fa3c1b631574c178883fe58675ff6dd
38 rdf:rest N73cb8a0c43804a02a72953fd15d15da5
39 N3b6d2b86963f45f39a1df59ebe971aaa schema:affiliation https://www.grid.ac/institutes/grid.14442.37
40 schema:familyName Uner
41 schema:givenName Aysegul
42 rdf:type schema:Person
43 N3fa3c1b631574c178883fe58675ff6dd schema:affiliation https://www.grid.ac/institutes/grid.14442.37
44 schema:familyName Kilickap
45 schema:givenName Saadettin
46 rdf:type schema:Person
47 N6a34873c00df42b1a00317d17b8fef9d rdf:first Na2dd3f3d34a446f4bc204b18bafeecf1
48 rdf:rest N91a019d22bb14f40bf6a6400220514d0
49 N73cb8a0c43804a02a72953fd15d15da5 rdf:first Nee098642cf0a467fa3eb59a1000e900e
50 rdf:rest Ndecce884df2e4c5ba655c89a535ca5be
51 N89eb81fa6854430c9525757930fdcc25 schema:affiliation https://www.grid.ac/institutes/grid.14442.37
52 schema:familyName Dizdar
53 schema:givenName Omer
54 rdf:type schema:Person
55 N91a019d22bb14f40bf6a6400220514d0 rdf:first N3b6d2b86963f45f39a1df59ebe971aaa
56 rdf:rest rdf:nil
57 Na2dd3f3d34a446f4bc204b18bafeecf1 schema:affiliation https://www.grid.ac/institutes/grid.14442.37
58 schema:familyName Erman
59 schema:givenName Mustafa
60 rdf:type schema:Person
61 Nc1115419ff914217ac3f9cec5f7e4c1e schema:name nlm_unique_id
62 schema:value 7806519
63 rdf:type schema:PropertyValue
64 Nd2140ae477f548a6942ed6207ae377cc schema:name pubmed_id
65 schema:value 30863883
66 rdf:type schema:PropertyValue
67 Ndecce884df2e4c5ba655c89a535ca5be rdf:first N89eb81fa6854430c9525757930fdcc25
68 rdf:rest N6a34873c00df42b1a00317d17b8fef9d
69 Ne5a5c55642564b1b82b3cf5f21d03c9c schema:name doi
70 schema:value 10.1007/s00280-019-03810-9
71 rdf:type schema:PropertyValue
72 Ne68487cd6b9e4887bdb1f8a4f51c8f1f schema:name readcube_id
73 schema:value 00ba3341e3054532101e612316f3547adadebb582f3ce26749a779c1f825e754
74 rdf:type schema:PropertyValue
75 Nee098642cf0a467fa3eb59a1000e900e schema:affiliation https://www.grid.ac/institutes/grid.14442.37
76 schema:familyName Onder
77 schema:givenName Sevgen
78 rdf:type schema:Person
79 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
80 schema:name Medical and Health Sciences
81 rdf:type schema:DefinedTerm
82 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
83 schema:name Cardiorespiratory Medicine and Haematology
84 rdf:type schema:DefinedTerm
85 sg:journal.1088364 schema:issn 0344-5704
86 1432-0843
87 schema:name Cancer Chemotherapy and Pharmacology
88 rdf:type schema:Periodical
89 https://doi.org/10.1016/s0140-6736(15)60294-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1015414635
90 rdf:type schema:CreativeWork
91 https://doi.org/10.1056/nejmoa1214886 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046181766
92 rdf:type schema:CreativeWork
93 https://doi.org/10.1056/nejmoa1408440 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005474865
94 rdf:type schema:CreativeWork
95 https://doi.org/10.1097/jto.0b013e3181c4dedb schema:sameAs https://app.dimensions.ai/details/publication/pub.1003976586
96 rdf:type schema:CreativeWork
97 https://doi.org/10.1200/jco.2010.33.7089 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024728994
98 rdf:type schema:CreativeWork
99 https://www.grid.ac/institutes/grid.14442.37 schema:alternateName Hacettepe University
100 schema:name Department of Medical Oncology, Hacettepe University Institute of Cancer, Hamamonu, 06100, Ankara, Turkey
101 Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey
102 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...